Physician profile
Benjamin Lam
NPI 1114980380
$10,236.63
in general payments reported to CMS, 2019-2025
23 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,037 · 2020: $1,163 · 2021: $1,939 · 2022: $1,254 · 2023: $2,939 · 2024: $287 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,843.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $3,460.99 | 2019-2025 | Xeomin |
| Musculoskeletal Transplant Foundation INC. | $1,289.11 | 2019-2021 | |
| Medical Device Business Services, INC. | $1,118.81 | 2019 | |
| Sientra, INC. | $1,042.48 | 2021-2023 | Sientra High Strength Cohesive Silicone Gel Breast Implant |
| Allergan, INC. | $771.64 | 2019-2022 | |
| Smith+Nephew, INC. | $681.76 | 2019-2025 | Collagenase Santyl, Stravix Pl, Oasis Micro |
| Kerecis Limited | $389.83 | 2021-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Mentor Worldwide LLC | $352.75 | 2019-2022 | |
| Tela Bio, INC. | $237.07 | 2019-2021 | |
| Avita Medical Americas, LLC | $141.46 | 2023 | Recell |
| Acelrx Pharmaceuticals, INC. | $109.56 | 2021 | |
| Axogen | $106.66 | 2019 | |
| Galderma Laboratories, L.P. | $99.70 | 2021-2025 | Dysport |
| Revance Therapeutics, INC. | $87.18 | 2025 | Daxxify |
| Abbvie INC. | $86.68 | 2023-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Access Pro Medical, LLC | $70.61 | 2025 | Matriderm |
| Integra Lifesciences Corporation | $65.94 | 2019-2025 | Integra, Surgimend, Omnigraft |
| Organogenesis INC. | $36.45 | 2021 | |
| Davol INC. | $28.87 | 2019 | |
| Progenacare Global, LLC | $17.20 | 2024 | |
| Motiva USA, LLC | $15.71 | 2025 | |
| Elutia, INC. | $14.31 | 2021 | |
| Acell, INC. | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.